This article was originally published in May 2022. Sen. Durbin’s bill is still alive; a version of it has also been added to a piece of legislation that must pass by the end of September this year, S. 4348, the Senate’s FDA user fee reauthorization legislation. We have to keep up the pressure in Congress opposing this bill. Over the last few months, we’ve been reporting on the serious consequences of enacting mandatory product registration for supplements—for example, the major threat to higher-dose supplements and to supplement choices more generally. Read more.